Metoclopramide Noridem (Metoclopramide Hydrochloride Monohydrate)

The drug blocks dopamine D2 receptors in the brain’s chemoreceptor trigger zone, which suppresses the vomiting reflex. At the same time it enhances acetylcholine release in the gastrointestinal tract, stimulating smooth‑muscle contractions that promote faster gastric emptying.

Dosing is individualized and must be determined by a qualified prescriber based on the patient’s condition, age, renal function and route of administration. The prescribing clinician will decide the appropriate amount and frequency.

Safety data for Metoclopramide during pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Metoclopramide differs from many antiemetics by combining dopamine antagonism with pro‑kinetic activity. Unlike pure serotonin antagonists such as ondansetron, it also accelerates gastric emptying, making it useful for gastroparesis. However, it carries a higher risk of extrapyramidal side effects compared with some newer agents.

The injectable solution should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and discard any solution that appears discolored or contains particles.

Metoclopramide Noridem is given by intramuscular or intravenous injection. The route, volume and rate of administration are determined by the prescribing clinician, who will also monitor the patient for therapeutic response and any adverse reactions.

Serious adverse events include extrapyramidal symptoms such as dystonia or akathisia, tardive dyskinesia with long‑term use, and rare but life‑threatening conditions like neuroleptic malignant syndrome. Immediate medical attention is required if these signs appear.

Patients with known hypersensitivity to metoclopramide or any component of the formulation should avoid it. Individuals with a history of severe movement disorders, uncontrolled epilepsy, or those taking monoamine oxidase inhibitors should not receive the drug without specialist guidance.